Vacuna triple vírica como tratamiento de verruga subungueal recalcitrante / Mumps, Measles, and Rubella Vaccine for the Treatment of a Recalcitrant Subungual Wart

No disponible

Panarteritis nudosa con patrón de respuesta inflamatoria sistémica: respuesta a anti-TNF / Polyarteritis Nodosa with a Systemic Inflammatory Response Pattern: Effectiveness of anti-TNF

No disponible

Liquen plano palmoplantar: espectro de manifestaciones clínicas en un paciente / Palmoplantar Lichen Planus: The Spectrum of Clinical Manifestations in a Single Patient

No disponible

Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium.

BACKGROUND: Advanced-stage mycosis fungoides (MF)/Sézary syndrome (SS) patients are weighted by an unfavorable prognosis and share an unmet clinical need of effective treatments. International guidelines are available detailing treatment options for the different stages but without recommending treatments in any particular order due to lack of comparative trials. The aims of this second CLIC study were to retrospectively analyze the pattern of care worldwide for advanced-stage MF/SS patients, the distribution of treatments according to geographical areas (USA versus non-USA), and whether the heterogeneity of approaches has potential impact on survival. PATIENTS AND METHODS: This study included 853 patients from 21 specialist centers (14 European, 4 USA, 1 each Australian, Brazilian, and Japanese). RESULTS: Heterogeneity of treatment approaches was found, with up to 24 different modalities or combinations used as first-line and 36% of patients receiving four or more treatments. Stage IIB disease was most frequently treated by total-skin-electron-beam radiotherapy, bexarotene and gemcitabine; erythrodermic and SS patients by extracorporeal photochemotherapy, and stage IVA2 by polychemotherapy. Significant differences were found between USA and non-USA centers, with bexarotene, photopheresis and histone deacetylase inhibitors most frequently prescribed for first-line treatment in USA while phototherapy, interferon, chlorambucil and gemcitabine in non-USA centers. These differences did not significantly impact on survival. However, when considering death and therapy change as competing risk events and the impact of first treatment line on both events, both monochemotherapy (SHR = 2.07) and polychemotherapy (SHR = 1.69) showed elevated relative risks. CONCLUSION: This large multicenter retrospective study shows that there exist a large treatment heterogeneity in advanced MF/SS and differences between USA and non-USA centers but these were not related to survival, while our data reveal that chemotherapy as first treatment is associated with a higher risk of death and/or change of therapy and thus other therapeutic options should be preferable as first treatment approach.

Molluscum contagiosum gigantes recalcitrantes en pacientes infectados por VIH: respuesta terapeútica a los nuevos fármacos antiretrovirales (antiproteasas) / Recalcitrant giant molluscum contagiosum in HIV-infected patients: terapeutic response in relation with news antiretroviral drugs (antiproteases)

Molluscum contagiosum (MC) es frecuente en los pacientes infectados por VIH. Diversas publicaciones han establecido unas características clinicas frecuentemente atipicas con un curso progresivo y recalcitrante al tratamiento. MC en el paciente inmunocomprometido varía desde pápulas umbilicadas tipicas a grandes placas que pueden ulcerarse.MC gigante (>1cm) han sido descrito como un marcador de importante descenso del número de linfocitos T-helper.Nosotros describimos a dos pacientes infectados por VIH, con MC gigantes en cara y cuello, inmunodeficiencia avanzada y elevada carga viral. Sus lesiones solo se resolvieron con una combinación de quimioterapia antiretroviral que incluyó drogas antiproteasas (AU)

Lichen myxoedematosus associated with human immunodeficiency virus infection--report of two cases and review of the literature.

Lichen myxoedematosus (LM), or papular mucinosis, is an uncommon papular eruption caused by the dermal deposition of mucin. Three clinical forms can be distinguished, namely localised, disseminated (involving more than one site), and generalised LM, the last is called scleromyxoedema, and demonstrates erythema and skin sclerosis. Paraproteinaemia, often consisting of an abnormal IgG with lambda light chains, is usually present in patients with LM. Visceral involvement has also been documented. An association between LM and human immunodeficiency virus (HIV) infection has been reported recently. We now describe two further HIV-positive patients with LM and present a review of the literature regarding this association.

Primary cutaneous extramedullary plasmacytoma secreting lambda IgG.

An adult male was described, who developed a tumour on his left arm, which was diagnosed as a primary cutaneous extramedullary plasmacytoma after histopathological, electron microscopic and immunocytochemical studies. Further studies ruled out the presence of multiple myeloma, extramedullary plasmacytoma of another site, or paraproteinaemia/paraproteinuria. During a relapse of the tumour 2 1/2 years after initial treatment, a new immunocytochemical study demonstrated that the tumour cells expressed monoclonal lambda IgG at the intracytoplasmic level, an unusual finding.

Cutaneous lesions in severe combined immunodeficiency: two case reports and a review of the literature.

Two patients with severe combined immunodeficiency (SCID) in whom cutaneous lesions were the first clinical feature were studied. Neither the morphology nor the histology of the lesions was uniform, although we have noted some common findings that can, in subsequent cases, lead us to suspect SCID. The immunologic defects were not uniform, representing the two poles of the spectrum of SCID. We believe that early recognition of the skin lesions is very important, since the patient's life expectancy can be increased by a bone marrow transplantation (1).